DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE 
PUBLIC HEALTH SERVICE 
NATIONAL INSTITUTES OF HEALTH 
RECOMBINANT DNA ADVISORY COMMITTEE 
MINUTES OF MEETING 1 
MARCH 6-7, 1980 
The Recombinant ENA Advisory Committee (RAC) was convened for its eighteenth 
meeting at 9 a.m. on March 6, 1980, in Wilson Hall, Building 1, National 
Institutes of Health, 9000 Rockville Pike, Be the sd a, Maryland. Et. Jane K. 
Setlow, (Chairman) Biologist, Brookhaven National Laboratory, presided. In 
accordance with Public Law 92-463 the meeting was open to the public, except 
for the review of proposals involving proprietary information as the last item 
of business on March 7, 1980. 
Committee members present for all or part of the meeting were : 
Dr. Abdul Karim Ahmed; Dr. David Baltimore; Dr. Kenneth Bems, Dr. Winston 
Brill; Dr. Francis Broadbent; Dr. Allan Campbell; Mrs. Zelma Cason; Dr. Richard 
Goldstein; Dr. Susan Gottesman; Dr. Jean Harris; Ms. Patricia King; Dr. Sheldon 
Krimsky; Dr. Werner Maas; Dr. James Mason; Dr. Elena Nightingale; Dr. David 
Parkinson; Dr. Samuel Proctor; Mr. Ray Thornton; Dr. LeRoy Walters; Dr. Luther 
Williams; Dr. Frank Young; Dr. Milton Zaitlin; and Dr. William J. Gartland, Jr., 
Executive Secretary. 
A Committee roster is attached. (Attachment I) 
The following ad hoc consultants to the Committee were present : 
Dr. Robert W. McKinney, Enviro Control, Inc., Rockville, Maryland 
The following non-voting members and liaison representatives were present : 
Dr. Walter R. Dowdle, Center for Disease Control; Dr. Timothy J. Henry, Food 
and Drug Administration; Dr. Herman Lewis, National Science Foundation; Dr. David 
Logan, United States Department of Labor; Mr. Melvin Myers, National Institute 
for Occupational Safety and Health; Dr. Jane Schultz, Veterans Administration; 
Dr. Sue Tblin, United States Department of Agriculture; and Dr. William J. 
Walsh, III, Department of State. 
1 The RAC is advisory to the NIH, and its recommendations should not 
be considered as final and accepted. The Office of Recombinant ENA 
Activities should be consulted for NIH policy on specific issues. 
[ 36 ] 
